Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 3Dermatologic 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Neoplasms 2Neoplasm Metastasis 2Melanoma 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Ovarian Neoplasms 1Lymphoma 1Lung Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 181Nivolumab 117Ipilimumab 97Dacarbazine 48trametinib 37dabrafenib 353-ingenyl angelate 35Vemurafenib 33cemiplimab 27atezolizumab 24Temozolomide 24binimetinib 23Paclitaxel 22Imiquimod 22encorafenib 17avelumab 17Carboplatin 17Aminolevulinic Acid 17spartalizumab 16cobimetinib 16Cyclophosphamide 15Cisplatin 15Fluorouracil 14talimogene laherparepvec 13HhAntag691 11Gels 11Drug Therapy 11Bevacizumab 11lenvatinib 10durvalumab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × ALT-801 × Dermatologic × Clear all
NCT01029873 2016-10-27

QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma

Altor BioScience

Phase 1/2 Completed
25 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis, Neoplasms

NCT00496860 2013-07-22

Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies

Altor BioScience

Phase 1 Completed
26 enrolled 13 charts
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡